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To determine the effect of treatment of recurrent ischemia after 
reperfusion for acute myocardial infarction on in-hospital mortal-
ity and left ventricular function recovery and to identify patients 
at highest risk of serious consequences in the event of recurrent 
ischemia in this setting, 405 consecutively treated patients were 
studied retrospectively. All patients received intravenous throm-
bolytic therapy within 6 h of ST segment elevation-documented 
infarction and had angiographic confirmation of their reperfusion 
status performed within 120 min of treatment. 
Three hundred three patients had successful reperfusion with 
or without rescue angioplasty and had no recurrent ischemia 
(group 1), 74 patients had initially successful reperfusion but 
subsequent recurrent ischemia (group 2) and 28 patients had 
failed reperfusion (group 3). The in-hospital mortality in groups 1 
to 3 was 2.0%, 14.9% and 32.1 %, respectively (p < 0.001) and 
the change from baseline to prehospital discharge left ventricular 
ejection fraction was 1.2 ± 9.3%, -0.8 ± 8.7% and -4.3 ± 
Treatment of acute myocardial infarction with intravenous 
thrombolytic therapy has clearly been demonstrated to im-
prove patient survival (1-4) and, to a lesser but significant 
extent, to improve left ventricular functional recovery (5-8). 
However, recurrent in-hospital ischemia develops in 5% to 
18% of patients depending on the definition and perhaps on 
the thrombolytic regimen utilized (9-11) and has been asso-
ciated with worsened in-hospital survival (12,13). The effect 
of the success and timing of treatment of recurrent ischemia 
and the patients at highest risk for adverse outcomes with 
recurrent ischemia have not been identified. Better under-
standing of the outcome of treatment of recurrent ischemia 
might allow optimal management and decision concerning 
interhospital transfer of patients who have been treated with 
thrombolytic therapy for acute myocardial infarction. 
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5.3%, respectively (p = NS). Within the recurrent ischemia group 
(group 2), multiple regression analysis found absence of cardio-
genic shock at presentation (p = 0.002) and successful treatment 
initiated within 90 min of recurrent ischemia (p = 0.045) to be the 
only variables independently correlated with in-hospital survival. 
Later successful reperfusion was not associated with improved 
hospital survival. The timing and success of treatment did not 
affect recovery of global or regional left ventricular function in the 
patients with paired angiographic studies. 
Thus, 1) recurrent ischemia after successful reperfusion for 
acute myocardial infarction was associated with decreased in-
hospital survival, 2) successful early treatment of ischemia in this 
setting was associated with improved survival compared with later 
successful treatment or unsuccessful treatment at any time, and 3) 
mortality risk with recurrent ischemia was not easily stratified 
with readily available clinical variables. 
(J Am Coll CardioI1991;17:752-7) 
Methods 
Study patients. From January 5, 1984 through January 
12, 1990, 822 patients were treated for acute myocardial 
infarction with intravenous thrombolytic or mechanical 
reperfusion therapy and had urgent angiographic definition 
of their coronary anatomy at the University of Michigan. All 
patients had given informed consent for the procedure based 
on guidelines provided by the University of Michigan Med-
ical School Committee to Review Investigation Involving 
Human Beings. Data on these patients have been prospec-
tively coded on standard case report forms and entered into 
the University of Michigan Interventional Cardiology Data-
bank. 
For the purpose of this study, all patients meeting the 
following criteria were identified: 1) presentation with ST 
segment elevation 2:2 mm in two or more contiguous pre-
cordial electrocardiographic (ECG) leads or 2: 1 mm in two 
or more contiguous limb leads, 2) treatment with intravenous 
thrombolytic therapy within 6 h of clinical presentation and 
3) angiographic evaluation of coronary artery patency within 
120 min of the initiation of thrombolytic therapy. Supple-
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mental use of coronary angioplasty was allowed but not 
required. 
Four hundred five patients fulfilled these criteria; 309 of 
these patients were treated in one of the Thrombolysis and 
Angioplasty in Myocardial Infarction (TAM!) trials, the 
entry requirements and treatment protocols of which have 
been previously published (14). After initial treatment pa-
tients routinely received aspirin, 80 to 325 mg daily, and a 
calcium channel antagonist throughout their hospital stay 
and they received intravenous heparin adjusted to maintain 
the partial thromboplastin time one and one-half to two times 
the control level for at least 24 h. Pre hospital discharge 
angiography was routinely encouraged during the study 
period. 
Triage to treatment of recurrent ischemia. Patients rou-
tinely underwent continuous ECG monitoring for 2:.72 h after 
presentation. Clinical suspicion of recurrent ischemia 
prompted immediate evaluation by a 12 lead ECG. Treat-
ment thereafter was individualized, largely on the basis of 
knowledge of the patient's presenting coronary anatomy as 
well as on the patient's hemodynamic status. Initial treat-
ment for almost all patients included sublingual and intrave-
nous nitrate therapy. Throughout the study period coronary 
angioplasty was considered the mainstay of treatment for 
recurrent ischemia except in patients who responded readily 
to nitrates, patients who were considered to be unsuitable 
for the procedure because they had multivessel coronary 
involvement or were more likely to benefit from bypass 
surgery or those whose infarct-related artery was small and 
its reocclusion was believed unlikely to have major conse-
quences. 
Angiographic analysis. Angiographic analyses were per-
formed by experienced observers who were unaware of 
clinical data. The Thrombolysis in Myocardial Infarction 
(TIMI) flow pattern was determined visually (15). Pre- and 
postintervention percent diameter stenosis of the infarct-
related artery was determined by calipers. Global left ven-
tricular ejection fraction was determined from right anterior 
oblique angiograms with use of the area-length method (16). 
Regional wall motion in the infarct zone was determined 
with the centerline chord method (17). Ventriculograms 
were excluded from analysis for inadequate opacification 
and when no sinus beats were recorded within the first seven 
beats after injection of contrast medium. 
Definitions. Initially successful reperfusion was defined 
as TIMI flow 2:.2 (15) at initial angiography after the admin-
istration of intravenous thrombolytic therapy with or with-
out rescue angioplasty. Multivessel disease was defined as 
2:.50% diameter stenosis present in 2:. two of three major 
epicardial coronary vessels or a bypassable branch thereof. 
Recovery of global and regional left ventricular ejection 
fraction was defined as the improvement between the initial 
and prehospital discharge ventriculogram-derived left ven-
tricular ejection fraction and infarct zone regional wall 
motion. 
Recurrent ischemia was defined as the presence of at 
least two of the three following clinical variables: angina, ST 
segment changes consistent with new ischemia or re-
elevation of serum creatine kinase levels with isoenzyme 
confirmation. Clinically silent reocclusion documented only 
at follow-up angiography was not included in this definition. 
Successful treatment of recurrent ischemia was defined as 
the elimination of angina and ST segment changes suggestive 
of ischemia (clinical patency) and (in patients undergoing 
immediate angiography) restoration of TIMI grade 3 flow. 
Time to treatment of recurrent ischemia was defined as 
the time from recurrent symptom onset to either repeat coro-
nary angiography, placing the patient on cardiopulmonary 
bypass before bypass surgery or the initiation of definitive 
medical therapy (intravenous thrombolytic therapy, if used 
without mechanical reperfusion, or intravenous heparin or 
nitroglycerin if neither intravenous thrombolytic therapy nor 
mechanical reperfusion was attempted), whichever occurred 
latest. This was determined by a careful review of physicians' 
and nurses' notes in the medical and catheterization laboratory 
record. When possible, this determination was made indepen-
dent of knowledge of the major clinical end points of this study. 
Because the restoration of adequate infarct artery flow with 
coronary angioplasty or medical therapy was often initially 
intermittent, the time to successful restoration of flow was not 
chosen as the index variable. 
Time to treatment of recurrent ischemia :::;90 min was 
prospectively identified to determine the effect of early 
treatment on patient outcome. The time 90 min was chosen 
as a reasonable time to initiation of therapy when a patient 
had ready access to a cardiac catheterization laboratory. 
Statistical analysis. All values are presented as mean 
values ± I SD unless otherwise noted. Comparison among 
patients with successful initial reperfusion and no recurrent 
ischemia (group I), successful initial reperfusion but recur-
rent ischemia (group 2) and unsuccessful reperfusion (group 
3) was made using analysis of variance methods for contin-
uous variables and chi-square analysis for categorical varia-
bles. Comparisons between survivors and non survivors 
within group 2 were made using the Student t test and 
chi-square analysis for continuous and categorical variables, 
respectively. MUltiple linear regression analyses were used 
within group 2 to determine the independent correlates of 
in-hospital survival and the recovery of global and regional 
left ventricular function. Given the number of patients and 
events studied, it was intended that this be an exploratory 
analysis; therefore, standard post-hoc entry into the regres-
sion analyses with alpha = 0.15 to enter and alpha = 0.15 to 
reject was performed (18). Statistical significance was as-
sumed when the null hypothesis could be rejected with 95% 
confidence (two-tailed testing). 
When a single patient had more than one ischemic event, 
the data were handled as follows: 1) For comparison of 
survival and left ventricular functional outcomes the patient 
was entered only once if the events were both treated 
successfully and the time to treatment was coded as indefi-
nite; if either event was treated unsuccessfully, then only the 
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Table 1. Patient Characteristics 
Group I Group 2 
(reperfusion, (reperfusion, 
no recurrent recurrent Group 3 
ischemia; ischemia; (no reperfusion; 
n = 303) n = 74) n = 28) 
Age (yr) 56 ± 10 56 ± II 60 ± 9 
Male gender (%) 76.9 82.7 71.4 
Prior myocardial 11.2 12.0 14.3 
infarction (%) 
Time to thrombolytic 3.1 ± 1.5 3.3 ± 1.6 3.3 ± 1.9 
therapy (h) 
Anterior myocardial 45.6 39.2 35.0 
infarction (%) 
Prior angina (%) 42.9 39.7 35.7 
Immediate coronary 58.4 54.0 75.0 
angioplasty (%) 
Tissue-type plasminogen 75.5 82.4 64.2 
activator therapy (%) 
Streptokinase therapy 21.8 13.5 14.3 
(%) 
Other thrombolytic 2.6 4.1 21.5 
regimen (%) 
Multivessel coronary 50.2 60.8 71.4 
disease (%) 
Cardiogenic shock (%) 0.7 2.7 3.6 
Baseline left ventricular 51 ± 12 50 ± 12 50 ± 14 
ejection fraction (%) 
Baseline infarct zone -2.58 ± 1.02 -2.64 ± 0.95 -2.68 ± 0.55 
regional wall motion 
(SD/chord) 
unsuccessfully treated event was analyzed . 2) For assess-
ment of the success of individual therapies all treatment 
attempts were analyzed. When coronary bypass surgery was 
performed without angiographic follow-up, successful reper-
fusion was assumed unless a perioperative death occurred, 
in which case necropsy data were evaluated, or unless 2:2 
new and contiguous Q waves developed in the territory of 
the infarct-related artery after bypass surgery. 
Results 
Baseline patient demographic data (Table 1). There were 
no significant differences among groups 1 to 3 with regard to 
patient age, infarct location, time to initiation of throm-
bolytic therapy, presence of multi vessel coronary disease or 
initial left ventricular ejection fraction. 
In-hospital patient survival and recovery of left ventricular 
function (Table 2, Fig. 1). Patients with successful initial 
reperfusion and no clinically evident recurrent ischemia 
(group 1) had an extremely low mortality (2.0%) and those 
without successful reperfusion (group 3) had a very high 
mortality (32.1 %). Patients with initially successful reperfu-
sion but subsequent recurrent ischemia (group 2) had an 
intermediate mortality (14.9%). No significant differences 
were noted among the groups with regard to recovery of left 
ventricular function. Recovery tended to be best when 
Table 2. Mortality and Left Ventricular Function 
Group I Group 2 
(reperfusion, (reperfusion, 
no recurrent recurrent Group 3 
ischemia: ischemia; (no reperfusion; 
n = 303) n = 74) n = 28) 
Death (%) 2.0t 14.9 32.1 
Change in left 1.2 ± 9.3 -0.8 ± 8.7 -4.3 ± 5.3t 
ventricular ejection 
fraction (%)* 
Change in infarct zone 0.50 ± 1.02 0.47 ± 1.04 -0.18 ± 0.37§ 
regional wall motion 
(%)* 
'From baseline to prehospital discharge catheterization, n = 208, 30 and 
10 for groups I, 2 and 3, respectively; tp < 0.001 versus reperfusion with 
recurrent ischemia: tp = 0.12 versus reperfusion with recurrent ischemia; 
§p = 0.14 versus reperfusion with recurrent ischemia. 
reperfusion was achieved without recurrent ischemia and 
recovery was worse when all attempts to achieve reperfu-
sion were unsuccessful. 
Restoration of coronary patency with angioplasty. "Re-
trieval" coronary angioplasty was attempted in 52 patients. 
Their mean age was 53 ± 10 years; 86% were male and 56% 
had multivessel disease. Their initial left ventricular ejection 
fraction was 51 ± 12% and dilation of 52 coronary sites was 
attempted (left anterior descending artery in 17, left circum-
flex artery in 4, right artery in 27 and a bypass graft in 4). 
Angioplasty was initiated at a median of 1.5 h after the onset 
of recurrent ischemic symptoms (range 0.2 to 12.2 h) and 
was successful at restoring patency in 39 (75%) of 52 vessels. 
Restoration of coronary patency with medical therapy. 
Sixteen patients were treated medically. Clinical coronary 
patency was achieved in 2 of the 3 patients treated with 
intravenous thrombolytic therapy and 2 of the 13 patients 
who were treated without thrombolytic therapy. 
Treatment of recurrent ischemia with emergency bypass 
surgery. Emergency bypass surgery was performed on 11 
patients, including 5 who had undergone clinically unsuc-
Figure I. Incidence of recurrent ischemia and the effect on in-
hospital mortality of recurrent ischemia in 405 patients. 
Initial Reperfusion. wilh .J 
Recurrent Ischemia Mortality 
(%) ~o ~.L-=====,,"-_.l.---'_.....J..n-:32-:-' l %....J..... j ~ D _ 
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Reperfusion Ischemia Reperfusion 
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Table 3. Correlates of In-Hospital Death After 
Recurrent Ischemia 
Clinical 
Age (yr) 
Anterior myocardial 
infarction (%) 
Arterial blood pressure 
(mm Hg) 
Bradycardia (:s50 bpm) 
before catheterization (%) 
Cardiogenic shock at 
presentation (%) 
Diabetes mellitus (%) 
Hypertension (%) 
Male gender (%) 
Prior angina pectoris (%) 
Prior myocardial infarction 
(%) 
Rales at presentation (%) 
Time to intravenous therapy 
(h) 
Ventricular tachycardia 
prior to catheterization 
(%) 
Angiographic 
Initial left ventricular 
ejection fraction (%) 
Multivessel disease (%) 
Proximal LAD occlusion 
(%) 
Proximal right coronary 
occlusion (%) 
Treatment 
Early coronary angioplasty 
(%)* 
Died 
(n = II) 
63 ± 9 
36.4 
115 ± 26 
18.2 
IS.2 
0.0 
33.3 
63.6 
30.0 
0.0 
IS.2 
3.4 ± 2.4 
IS.2 
47 ± 15 
90.9 
IS .2 
18.2 
54.5 
Survived 
(n = 63) 
55 ± II 
41.3 
\32 ± 27 
11.3 
0.0 
9.5 
49.2 
S5.7 
41.3 
14.3 
9.5 
3.3 ± 1.4 
12.7 
51 ± 12 
55.5 
12.7 
12.7 
53.1 
Univariate 
P 
0.01 
NS 
0.05 
NS 
0.01 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
0.02 
NS 
NS 
NS 
Time to treatment of 
recurrent ischemia 
(median, range [h]) 
Successful reperfusion (%) 
Successful reperfusion 
initiated within 90 min 
3.5 (1.4 to 28) 2.0 (0.2 to lOS) NS 
45.5 69.S NS 
0.0 39.7 0.03 
(%) 
*For failed thrombolysis or " high'risk" anatomy at initial catheterization: 
LAD = left anterior descending coronary artery . 
cessful coronary angioplasty. Treatment was initiated a 
median of 2.9 h after development of recurrent ischemia. 
Univariate and multivariate correlates of in-hospital sur-
vival after recurrent ischemia (Table 3, Fig. 2). Survival was 
correlated in univariate analysis with the absence of cardio-
genic shock at initial presentation, successful treatment 
initiated within 90 min of recurrent ischemia, younger pa-
tient age and higher blood pressure at initial presentation. 
Regression analysis found only shock and time to treatment 
to independently predict in-hospital outcome (death = 0.10 
+ 0.75 [shock] - 0.16 [successful treatment within 90 min); 
multiple r = 0.51, P < 0.01). Successful early (::;90 min) 
initiation of therapy was associated with a significantly lower 
Mortality 
(%) 
10 
Early 
Treatment 
Late 
Successful 
Treatment 
Failed 
Treatment 
Figure 2. Failure of late successful reperfusion to improve in-
hospital survival after recurrent ischemia in 74 patients. 
in-hospital mortality (0 of 25 = 0%) than in patients with 
successful later reperfusion (5 of 24 = 21%) or unsuccessful 
reperfusion (6 of 25 = 24%) (Fig. 2). 
Correlates of left ventricular functional recovery after 
recurrent ischemia. Paired left ventricular angiograms of 
sufficient quality for analysis were available in only 30 of the 
74 group 2 patients. In these patients only the presence of an 
anterior myocardial infarction was correlated with improved 
recovery of global left ventricular function as measured by 
ejection fraction (anterior = 3.7 ± 9.1% versus inferior = 
- 3.1 ± 7.0%; p = 0.04). There was a weak and nonstatisti-
cally significant trend toward improved recovery of function 
when successful reperfusion was achieved (successful reper-
fusion = 1.1 ± 8.2% versus unsuccessful reperfusion = - 3.8 
± 8.8%; p = 0.18). There were no correlates of improved 
infarct zone regional ejection fraction, although patients with 
single vessel disease tended to have improved recovery 
(single vessel = 0.97 ± 1.06 SD/chord versus multivessel = 
-0.02 ± 0.10 SD/chord; p = 0.07). 
Discussion 
The problem of recurrent postinfarction ischemia. The 
timely administration of intravenous thrombolytic agents to 
patients with acute myocardial infarction has markedly 
reduced the in-hospital mortality of selected patient groups 
(1-4). However, because none of these agents removes the 
underlying stimulus for thrombus formation, a propensity for 
recurrent thrombosis and ischemia remains. Recurrent 
ischemia occurs in up to 20% of patients in this setting and 
has been shown to be associated with an increase in in-
hospital mortality from approximately 50/0-10% to 100/0-20% 
(12, 13). In the mid 1980s several investigations were de-
signed to test the hypothesis that mechanical disruption 
(angioplasty) of the underlying atheroma and a reduction in 
the consequent "fixed" obstruction would lessen the risk of 
recurrent ischemia. The failure of this aggressive strategy to 
improve short-term survival or recovery of left ventricular 
contractility (19-21) has led to the widespread support of the 
approach of watchful waiting (22) , with cardiac catheteriza-
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tion reserved for patients who display postinfarction isch-
emia. It must be recognized, however, that these results 
came from trials in which most of the participating hospital 
centers could provide timely and aggressive interventional 
therapy to patients with recurrent ischemia. 
The consequences of early and successful treatment of 
ischemia in this setting and the determination of patients at 
highest risk for morbid outcome with recurrent ischemia 
have not been adequately studied. The implications of either 
a benefit or an inability to demonstrate the benefit of early 
aggressive therapy of recurrent ischemia would have consid-
erable ramifications regarding interhospital transfer of these 
often acutely ill patients from the community hospitals to 
which they are most often admitted. 
Animal studies of recurrent ischemia. In animal models 
(23) brief periods of ischemia consequent to coronary occlu-
sion may minimize necrosis from a second, temporally 
proximate period of ischemia, providing that the duration of 
the second occlusion is relatively short. Thus, several 5 min 
occlusions have been shown to limit infarct size when a 
subsequent 40 min coronary occlusion. but not a 3 h coro-
nary occlusion. is applied (23). This phenomenon is termed 
"preconditioning" and appears to affect infarct size but not 
to attenuate myocardial stunning (24). The effect of longer 
initial periods of coronary occlusion. as might occur in 
humans with acute myocardial infarction treated with throm-
bolytic therapy, on the consequences of a second coronary 
occlusion have not been evaluated. 
Results of therapy for recurrent ischemia. This study is 
the first to report on the effect of treatment of recurrent 
ischemia after thrombolytic therapy in a relatively large 
number of patients treated for acute myocardial infarction. 
Successful early (::;90 min) initiation of therapy for recurrent 
ischemia was associated with a significantly lower in-
hospital mortality (0%) than successful later reperfusion 
(21%) or unsuccessful reperfusion (24%). These figures 
compare with hospital mortalities of 2% and 32%, respec-
tively, for patients with successful reperfusion and no recur-
rent ischemia and patients with unsuccessful reperfusion 
after initial therapy. The favorable impact of early retreat-
ment on the recovery of left ventricular function in the 
relatively limited number of patients with paired ventriculo-
grams was much less pronounced and only a positive trend 
was demonstrated. 
Mechanisms of improved survival. The mechanism by 
which intravenous thrombolytic therapy improves patient 
survival is not well understood. It appears that only very 
early treatment of myocardial infarction with thrombolytic 
therapy markedly improves left ventricular functional recov-
ery (25). The modest improvement in left ventricular ejection 
fraction in most patients (5-8) appears disproportionate to 
the gain in survival, leading to speculation that changes in 
the threshold for malignant ventricular arrhythmias (26), 
improved infarct healing (27) or other factors may be con-
tributing beneficial mechanisms. Because of the small im-
provement in recovery of left ventricular ejection fraction 
with successful thrombolysis (5-8), it is not surprising that 
successful treatment of recurrent ischemia also appears not 
to have a major impact on left ventricular functional recov-
ery. The mechanism of improved survival with early suc-
cessful treatment of recurrent ischemia then remains some-
what enigmatic, but demonstration of this relation does 
provide further support for the prognostic importance of an 
open coronary artery after myocardial infarction (28,29). Of 
the 11 deaths in this series, 6 were attributed to primary left 
ventricular dysfunction and 4 were attributed to multisystem 
failure with left ventricular dysfunction as a contributing 
factor. Perhaps if the patients who died had been serially 
restudied and if their left ventricular functional recovery had 
been found to be especially poor, a beneficial effect of 
successful secondary reperfusion by means of relative im-
provement of left ventricular function might have been 
demonstrated. 
Limitations. The results of this study should be viewed in 
the context of its limitations. First. this is a retrospective 
study in which a key variable, time to treatment of recurrent 
ischemia, was not prospectively recorded. Careful and un-
biased chart review usually allowed an accurate assessment 
of this variable. but errors of 15 to 20 min due to imprecise 
timing of events were probably not uncommon. The inherent 
inaccuracies of measuring time from chest pain onset and 
time to reperfusion consequent to changing flow patterns 
with incomplete coronary obstruction should also be ac-
knowledged. In fact, reanalysis of the data using 60 and 
120 min, but not 150 min, cutoff points yielded similar 
results. A related compounding problem is that of the bias 
toward earlier treatment of the most gravely ill patients (30). 
This could have resulted in earlier therapy of those patients 
most likely to benefit from successful reperfusion as well as 
later treatment of patients with a smaller infarct in whom 
therapy might have had no effect on survival. 
Also, although a relatively small number of patients had 
recurrent ischemia, mUltiple subgroup analyses were per-
formed, leading to the possible identification of spurious 
associations. The previously demonstrated marked survival 
benefit with very early treatment of myocardial infarction 
(1,2) lends credence to the conclusions of this study and 
makes an invalid conclusion less likely (31). Finally, com-
pared with current treatment strategies based on the findings 
of randomized trials (18-20), a large proportion of patients 
analyzed in this study received coronary angioplasty early 
for failed thrombolysis or "high risk" anatomy. Although 
early angioplasty was not an independent correlate of in-
hospital survival, it is possible that the inclusion of such 
patients might slightly bias the stated results. 
Clinical implications. Given the facts that up to 20% of 
patients treated with intravenous thrombolytic therapy will 
have recurrent ischemia (9-11), that this process appreciably 
increases in-hospital mortality (12,13), that patients likely to 
have recurrent ischemia and its major consequences are 
difficult to identify prospectively (32) and that early treat-
ment of recurrent ischemia appears to improve patient 
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survival, it appears that all patients treated with intravenous 
thrombolytic therapy should have rapid access to facilities 
where secondary reperfusion can be readily obtained. It is 
not known whether a second administration of a throm-
bolytic regimen can match the 75% reperfusion rates with 
"retrieval" coronary angioplasty in this setting. Preliminary 
reports suggest high initial patency, but also frequent recur-
rent ischemia, when tissue-type plasminogen activator is 
readministered (33). Until sustained efficacy can be demon-
strated, we recommend that provisions be made for inter-
hospital transfer to cardiac catheterization facilities within 
60 to 120 min of recurrent ischemia for all patients undergo-
ing thrombolytic therapy. 
We express our gratitude for the expert secretarial assistance provided by 
Kevin Handy and Lin Nicholson. 
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